Two humanized anti-GPC3 antibody-drug conjugates (hYP7 and hYP9.1b) in the IgG format have been reported to induce antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in GPC3-positive cancer cells [102]. The gene discussed is GPC3; the disease is cancer.